This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01277/identifier/kegg-drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01277/identifier/drugbank/
n15http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01277/identifier/national-drug-code-directory/
n4http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://www.rxlist.com/cgi/generic/
n10http://linked.opendata.cz/resource/drugbank/patent/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/ontology/mesh/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01277/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n19http://www.drugs.com/cdi/
n17http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01277
rdf:type
n5:Drug
n5:description
Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1). IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human IGF-1. The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.
n5:dosage
n23:271B6280-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Keating GM: Mecasermin. BioDrugs. 2008;22(3):177-88. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18481900 # Rosenbloom AL: Mecasermin (recombinant human insulin-like growth factor I). Adv Ther. 2009 Jan;26(1):40-54. Epub 2009 Jan 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19198769 # Kemp SF: Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options. BioDrugs. 2009;23(3):155-63. doi: 10.2165/00063030-200923030-00002. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19627167 # Rosenbloom AL: Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature? Lancet. 2006 Aug 12;368(9535):612-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16905026 # Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, Vaught JL: Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol. 1993 Nov;124(1):73-88. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8282084
n5:group
approved investigational
n5:halfLife
2 hours
n5:indication
For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.
owl:sameAs
n4:DB01277 n24:DB01277
dcterms:title
Mecasermin
adms:identifier
n7:DB01277 n18:PA164774876 n21:D04870 n22:15054-1040-5
n5:mechanismOfAction
Mecasermin supplies recombinant-DNA-origin IGF-1, which binds to the Type I IGF-1 receptor. This receptor exerts intra-cellular signaling activity in a number of processes involved in statural growth, including mitogenesis in multiple tissue types, chondrocyte growth and division along cartilage growth plates, and increases in organ growth.
n5:packager
n16:271B627C-363D-11E5-9242-09173F13E4C5 n16:271B627E-363D-11E5-9242-09173F13E4C5 n16:271B627D-363D-11E5-9242-09173F13E4C5
n5:patent
n10:5681814 n10:5200509
n5:routeOfElimination
Both the liver and the kidney have been shown to metabolize IGF-1.
n5:synonym
Somatomedin-C IGF-1 Mechano growth factor IGF1 Insulin-like growth factor 1 Mecasermin rinfabate
n5:toxicity
There is no clinical experience with overdosage of mecasermin. Based on known pharmacological effects, acute overdosage would be predicted to lead to hypoglycemia. Long-term overdosage may result in signs and symptoms of acromegaly.
n5:volumeOfDistribution
* 0.257 ± 0.073 L/kg [subjects with severe Primary IGFD]
n5:proteinBinding
In blood, IGF-1 is bound to six IGF binding proteins, with > 80% bound as a complex with IGFBP-3 and an acid-labile subunit.
n14:hasConcept
n15:M0337463
foaf:page
n12:increlex.htm n19:mecasermin.html
n5:Molecular-Formula
n17:271B6282-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n17:271B6281-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:H01AC03
n5:absorption
While the bioavailability of rhIGF-1 after subcutaneous administration in healthy subjects has been reported to be close to 100%, the absolute bioavailability of mecasermin given subcutaneously to subjects with primary insulin-like growth factor-1 deficiency (Primary IGFD) has not been determined.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
68562-41-4
n5:containedIn
n20:271B627F-363D-11E5-9242-09173F13E4C5